Drug trials in dementia: Challenging ethical dilemmas

Current Alzheimer Research

Volumn 4, Issue 4, 2007, Pages 468-472

  Korczyn, Amos D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT;

CAREGIVER; COGNITION; COMA; CONFERENCE PAPER; DEMENTIA; HUMAN; INFORMED CONSENT; INSTITUTIONAL REVIEW; INSURANCE; MEDICAL ETHICS; PATIENT; PRIORITY JOURNAL; PSYCHOSIS; RISK;

CLINICAL TRIALS AS TOPIC; DEMENTIA; ETHICS, MEDICAL; HUMANS; INFORMED CONSENT; PATIENT SELECTION; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 34548699925     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507781788909     Document Type: Conference Paper

References (19)

1. Dresser R. The conscious incompetent patient. Hastings Center Report (2002).
2. Wendler D. Informed consent, exploitation and whether it is possible to conduct human subjects research without either one. Bioethics ISSN; 14:310-339 (2000).
3. Post G. Full-spectrum proxy consent for research participation when persons with Alzheimer disease lose decisional capacities: Research ethics and the common good. Alzh Dis Assoc Disord S3-S11 (2003).
4. Dresser R. Mentally disabled research subjects: The enduring policy issues. JAMA 276:67-72 (1996).
5. Pucci E, Belardinelli N, Borsetti G, Rodriguez D, Signorino M. Information and competency for consent to pharmacologic clinical trials in Alzheimer disease: An empirical analysis in patients and family caregivers. Alzheimer Dis Assoc Disord 15:146-154 (2001).
6. ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 39:799-803 (1998).
7. Kim YHK, Caine ED, Currier GW, Leibovici A, Ryan JM. Asessing the competence of persons with Alzheimer's disease in providing informed consent for participation in research. Am J Psychiatry 158:712-717 (2001).
8. Truog RD. Is informed consent always necessary for randomized, controlled trials? New Engl J Med 340:804-807 (1999).
9. Elad P, Treves TA, Drory M, et al. Demented patients' participation in a clinical trial: factors affecting the caregivers' decision. Int J Geriatr Psychiatry 15:325-330 (2000).
10. Hanley B, Truesdale A, King A, Elbourne D, Chalmers I. Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. BMJ 322:519-523 (2001).
11. Karlawish JHT, Whitehouse P. Is the placebo control obsolete in a world after donepezil and vitamine E? Arch Neurol 55:1420-1424 (1998.
12. Koops L, Lindley RI. Thrombolysis for alcute ischaemic stroke: consumer involvement in design of new randomised controlled tiral. BMJ 325:415-417 (2002).
13. Thornton H. Thrombolysis for acute ischaemic stroke. Good quality research that addresses patients' needs is required.. BMJ 325:1363 (2002).
14. Korczyn AD, Davidson M. Quality of life in Alzheimer's disease. Europ J Neurol 6:487-489 (1999).
15. Knopman D, Kahn J, Miles S. Clinical research designs for emerging treatments for Alzheimer disease.m Moving beyond placebocontrolled trials. Arch Neurol 55:1425-1429 (1998).
16. Treves TA, Verchovsky R, Klimovitzky SS, Korczyn AD. Recruitment rate to drug trials for dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 14:209-211 (2000).
17. Mastwyk M, Macfarlane S, LoGiudice D, Sullivan K.A. Why participate in an Alzheimer's disease clinical trial? Is it of benefit to carers and patients? International Psychogeriatrics 15:149-156 (2003).
18. Zinet GD, Fortenberry D, Blythe MB. Adolescents' attitudes about HIV immunization. J Pedriatric Psychol 24:67-75 (1999).
19. International Conference on Harmonisation. Guidance for industry. E6 good clinical practice: consolidated guidance. (1996).